A policy framework for leveraging generative AI to address enduring challenges in clinical trials.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 39815025.
- Also identified by DOI 10.1038/s41746-025-01440-5 and PMC identifier 11736117.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Can artificial intelligence improve clinical trial design? Despite their importance in medicine, over 40% of trials involve flawed protocols. We introduce and propose the development of application-specific language models (ASLMs) for clinical trial design across three phases: ASLM development by regulatory agencies, customization by Health Technology Assessment bodies, and deployment to stakeholders. This strategy could enhance trial efficiency, inclusivity, and safety, leading to more representative, cost-effective clinical trials.